Spots Global Cancer Trial Database for Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Official Title: A Multi-Center Phase 2 Study of Combined Modality Treatment With Ruxolitinib, Decitabine, and Donor Lymphocyte Infusion for Post-Transplant Relapse of AML or MDS
Study ID: NCT04055844
Study Description
Brief Summary: This is a multi-center, single-arm, open-label, phase II trial for the frontline treatment of relapsed AML or MDS following allo-HCT. Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
Detailed Description:
Eligibility
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Washington University Medical School, Saint Louis, Missouri, United States
University of Rochester Medical Center, Rochester, New York, United States
Contact Details
Name: Armin Rashidi, MD, PhD
Affiliation: Division of Hematology, Oncology and Transplantation, University of Minnesota
Role: PRINCIPAL_INVESTIGATOR
Name: Mark A Schroeder, M.D.
Affiliation: Washington University School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: John F Dipersio, M.D., Ph.D.
Affiliation: Washington University School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: Eric Huselton, M.D.
Affiliation: University of Rochester
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
